CYAN · XBRL financial data

Cyanotech financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CYAN's year ends in late March)

In thousands of dollars	FY 2020Mar 31, 2020	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025
Revenue from contracts with customers	31,899	32,345	35,968	23,178	23,071	24,215
Cost of goods and services sold	19,199	21,228	22,402	15,919	17,126	17,339
Gross profit	12,700	11,117	13,566	7,259	5,945	6,876
Research and development	608	639	712	770	689	449
General and administrative	5,281	4,876	5,367	4,659	4,464	4,397
Total operating expenses	11,647	11,033	10,992	10,179	10,537	9,384
Operating income (loss)	1,053	84	2,574	(2,920)	(4,592)	(2,508)
Interest expense	657	550	392	502	668	687
Income tax expense (benefit)	9	3	28	18	7	8
Net income (loss)	387	920	2,154	(3,440)	(5,267)	(3,203)
Earnings per share, basic USD per share	0.06	0.15	0.35	(0.55)	(0.81)	(0.45)
Earnings per share, diluted USD per share	0.06	0.15	0.35	(0.55)	(0.81)	—
Weighted average shares, basic thousands of shares	5,956	6,070	6,157	6,244	7	7,071
Weighted average shares, diluted thousands of shares	5,961	6,200	6,168	6,244	7	—

Fiscal years (CYAN's year ends in late March)

In thousands of dollars	FY 2020Mar 31, 2020	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025
Cash and cash equivalents	2,417	3,767	2,589	974	707	257
Accounts receivable	2,154	2,436	3,664	1,331	2,102	1,953
Inventory	9,653	8,415	9,466	10,707	7,313	7,788
Prepaid and other current assets	504	488	545	484	469	547
Total current assets	14,728	15,106	16,264	13,496	10,591	10,545
Property and equipment, net	13,042	12,136	11,885	11,366	10,109	8,927
Right-of-use asset	3,834	3,517	3,787	4,776	4,284	3,902
Total assets	31,787	30,879	32,045	29,728	25,112	23,490
Accounts payable	2,137	2,287	2,362	1,021	1,439	2,217
Accrued liabilities	849	844	1,412	1,101	757	715
Current portion of long-term debt	2,689	2,210	490	5,409	5,630	2,886
Total current liabilities	6,359	5,808	4,821	8,103	8,554	10,243
Long-term debt	6,009	4,823	4,336	1,000	1,000	1,000
Lease liability, non-current	3,519	3,175	3,386	4,275	3,744	3,363
Total liabilities	15,941	13,838	12,558	13,381	13,298	14,606
Accumulated deficit	(17,268)	(16,348)	(14,194)	(17,634)	(22,901)	(26,104)
Total stockholders' equity	15,846	17,041	19,487	16,347	11,814	8,884
Total liabilities and equity	31,787	30,879	32,045	29,728	25,112	23,490
Common shares outstanding (cover page) thousands of shares	6,028	6,118	6,204	6,291	6,948	7,232

Fiscal years (CYAN's year ends in late March)

In thousands of dollars	FY 2020Mar 31, 2020	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025
Net income (loss)	387	920	2,154	(3,440)	(5,267)	(3,203)
Stock-based compensation	577	214	344	310	359	247
Depreciation and amortization	1,934	1,748	1,599	1,655	1,589	1,479
Net cash from operating activities	1,243	2,400	2,379	(2,100)	(455)	(1,193)
Net cash from investing activities	(224)	(760)	(1,270)	(1,068)	(381)	(247)
Proceeds from issuing common stock	—	—	0	0	388	0
Repayments of long-term debt	611	670	—	—	—	—
Net cash from financing activities	558	(290)	(2,287)	1,553	569	990
Net change in cash	1,577	1,350	(1,178)	(1,615)	(267)	(450)

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Cyanotech	649	6,976	108*	7.4M	—	Q2 FY25 10-QSep 30, 2025
Immucell	8,860	7,186	3,019*	9.1M	—	Q2 FY26 10-QJun 30, 2026
Aquestive Therapeutics	90,349	7,557	(7,046)*	125.7M	8.4 quarters	Q3 FY26 10-QSep 30, 2026
Intellia Therapeutics	106,128	7,659	(83,113)*	140.1M	5.3 quarters	Q2 FY26 10-QJun 30, 2026
Emmaus Life Sciences	2,808	6,318	1,693*	70.2M	—	Q2 FY26 10-QJun 30, 2026
Cue Biopharma	17,392	7,877	(29,004)*	7.3M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Alpha Cognition	41,384	6,093	(6,859)*	21.8M	6.0 quarters	Q2 FY26 10-QJun 30, 2026
LFTD Partners	1,504	8,705	(555)*	14.8M	2.7 quarters	Q2 FY26 10-QJun 30, 2026
Cumberland Pharmaceuticals	3,862	166	169*	15.0M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.